NDA 220106 · Priovant Therap
Lisraya
Brepocitinib Tosylate · Oral
NovelPriority reviewOrphanCDER novel approval, Aug 27, 2026: To treat dermatomyositis in adults
Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Aug 27, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
7
4 Phase 3, 2 recruiting
FAERS reports
8
6 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS SERIOUS INFECTIONS Patients treated with LISRAYA are at increased risk of developing serious bacterial, fungal, viral, and opportunistic infections that may lead to hospitalization or death. Reported infections with use of Janus kinase (JAK) inhibitors, including LISRAYA: Active tuberculosis (TB), which may present with pulmonary or extrapulmonary disease. Evaluate and test patients for latent and active TB infection prior to and during LISRAYA treatment. If positive, treat for TB. Monitor all patients for active TB during treatment including patients who tested negative of a latent TB infection prior to LISRAYA treatment. Invasive fungal infections. Patients with invasive fungal infections may present with disseminated, rather than localized, disease. Bacterial, viral, including...
What it is approved for
From the label in effect Nov 5, 2026.
LISRAYA is indicated for the treatment of dermatomyositis in adult patients. LISRAYA is a Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of dermatomyositis in adult patients. ( 1 ) Limitations of Use LISRAYA is not recommended for use in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs. Limitations of Use LISRAYA is not recommended for use in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs.
Mechanism: Brepocitinib is a Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor. In a cell-free isolated enzyme assay, brepocitinib had greater inhibitory potency at TYK2 and JAK1 than JAK2 (≥ 3.4-fold) and JAK3 (≥ 286-fold). The JAK family comprises cytoplasmic tyrosine kinases that mediate signal transduction of cytokine receptors to influence immune cell function. Within the signaling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs) which modulate intracellular activity including gene expression. JAKs mediate cytokine signaling through hetero-...
Therapeutic areas: Dermatology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 27, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelMedication Guide
1 products under this application
- LISRAYA · BREPOCITINIB TOSYLATE EQ 30MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Brepocitinib" as an intervention, any sponsor and status, largest first.
- A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior UveitisPivotal-lookingActive, not recruiting
Priovant Therapeutics, Inc.Industry
NCT06431373 · 371 participants · Start Sep 11, 2024 · Primary completion Sep 11, 2026
Drug: Brepocitinib PO QD; Placebo PO QD · For: Uveitis, Posterior; Uveitis, Intermediate; Uveitis
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 107 sites in all
- A Phase 2/3 Study of Brepocitinib in Adults With Lichen PlanopilarisPivotal-lookingRecruiting
Priovant Therapeutics, Inc.Industry
NCT07532603 · 342 participants (planned) · Start Mar 19, 2026 · Primary completion Dec 31, 2028
Drug: Oral Brepocitinib; Placebo · For: Lichen Planopilaris
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 61 sites in all
- A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With DermatomyositisPivotal-lookingCompleted
Priovant Therapeutics, Inc.Industry
NCT05437263 · 241 participants · Start Oct 31, 2022 · Primary completion Jul 17, 2025
Drug: Brepocitinib; Placebo · For: Dermatomyositis
Sites: Phoenix, Arizona; Scottsdale, Arizona; Irvine, California · 109 sites in all
- A Study of Brepocitinib in Adults With Cutaneous SarcoidosisPivotal-lookingRecruiting
Priovant Therapeutics, Inc.Industry
NCT06978725 · 168 participants (planned) · Start Apr 9, 2025 · Primary completion Dec 31, 2028
Drug: Oral Brepocitinib; Oral Placebo · For: Cutaneous Sarcoidosis
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 44 sites in all
Emma GuttmanAcademic, hospital or other
NCT05076006 · 51 participants · Start May 19, 2021 · Primary completion Sep 30, 2023
Drug: PF-06700841; Placebo · For: Cicatricial Alopecia
Sites: New York, New York
Priovant Therapeutics, Inc.Industry
NCT05523765 · 26 participants · Start Nov 14, 2022 · Primary completion Jul 30, 2024
Drug: Brepocitinib · For: Non-infectious Intermediate Uveitis; Non-infectious Posterior Uveitis; Non-infectious Pan Uveitis
Sites: Los Angeles, California; Palo Alto, California; Pasadena, California · 15 sites in all
Priovant Therapeutics, Inc.Industry
NCT06433999 · 5 participants · Start Aug 28, 2024 · Primary completion Feb 28, 2025
Drug: Brepocitinib · For: Dermatomyositis; Dermatomyositis, Adult Type
Sites: Scottsdale, Arizona
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- herpes zoster2
- acute respiratory failure1
- blood creatine phosphokinase increased1
- drug ineffective1
- dyspnoea1
- hot flush1
- interstitial lung disease1
- malaise1
- maternal exposure during pregnancy1
- pyrexia1
- rash1
- rhinovirus infection1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 1 |
| 2025 | 7 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Phase 3 Trial of Brepocitinib in Dermatomyositis.
Vleugels RA, Paik JJ, Bauer Ventura I, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A, Smolen JS, Ferreira RJO, et al. · Ann Rheum Dis 2024 · Systematic Review
- A phase 2a trial of brepocitinib for cicatricial alopecia.
David E, Shokrian N, Del Duca E, et al. · J Am Acad Dermatol 2025 · Clinical Trial, Phase II, Randomized Controlled Trial
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
King B, Guttman-Yassky E, Peeva E, et al. · J Am Acad Dermatol 2021 · Clinical Trial, Phase II, Multicenter Study
- Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa.
Kimball AB, Peeva E, Forman S, et al. · NEJM Evid 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Large-scale meta-analysis of infection risk with JAK-STAT inhibitors in 29,000 patients.
Krebs M, Gulyás L, Fazekas KK, et al. · J Eur Acad Dermatol Venereol 2026 · Meta-Analysis, Systematic Review
Sponsor: Priovant Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.